Jinsheng Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinsheng Zhu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Changlei Bao
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China (D.L., C.B., H.T.).
2 shared publications Aiai Chu
Department of Echocardiography, The Second Affiliated Hospital of Nanjing Medical University, Jiangsu, China (A.C.).
1 shared publicationAng Luo
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota Twin Cities, Minneapolis (A.L.).
1 shared publication- Ankit A. Desai
Department of Medicine, Indiana University, Indianapolis, Indiana
1 shared publication - Arnaud Gautier
Sorbonne Universite
1 shared publication - Benoît Lacombe
IPSiM, Univ Montpellier, CNRS, INRAE, Institut Agro, Montpellier, France
1 shared publication
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (10)
Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension is a progressive and life-threatening disorder characterized by elevated pulmonary arterial pressure, right ventricular hypertrophy, and eventual right heart failure. Omaveloxolone, an orally bioavailable synthetic triterpenoid recently approved for Friedreich’s ataxia, improves mitochondrial bioenergetics and restores redox homeostasis. We investigated whether pharmacological activation of NRF2 (nuclear factor erythroid 2–related factor 2) by Omaveloxolone confers therapeutic benefit in pulmonary hypertension (PH). METHODS: The effects of Omaveloxolone were evaluated in chronic hypoxia-induced PH in mice, monocrotaline-induced PH in rats, and sugen/hypoxia-induced PH in rats, together with studies in human pulmonary artery endothelial and smooth muscle cells. RESULTS: NRF2 expression and nuclear localization were reduced in PH lungs and hypoxia-exposed cells, whereas Omaveloxolone restored NRF2 activity and increased downstream antioxidant enzymes. In endothelial cells, Omaveloxolone reduced oxidative stress, suppressed inflammatory signaling, and inhibited endothelial-to-mesenchymal transition. In smooth muscle cells, it attenuated oxidative stress and normalized abnormal proliferation, migration, and apoptosis. Omaveloxolone reduced HIF (hypoxia-inducible factor)-2α accumulation in endothelial cells and inhibited HIF-1α stabilization in smooth muscle cells. NRF2 knockdown attenuated these effects, supporting pathway dependency. Omaveloxolone attenuated PH, reduced right ventricular hypertrophy and vascular remodeling, and improved right ventricular function across hypoxia, monocrotaline, and sugen/hypoxia models under both preventive and therapeutic regimens. CONCLUSIONS: These findings demonstrate that Omaveloxolone exerts disease-modifying effects in PH by activating NRF2-dependent cytoprotective pathways, reducing oxidative stress, and suppressing inflammation, supporting its translational potential as a therapeutic strategy.
- 1 October 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (10)
Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension is a progressive and life-threatening disorder characterized by elevated pulmonary arterial pressure, right ventricular hypertrophy, and eventual right heart failure. Omaveloxolone, an orally bioavailable synthetic triterpenoid recently approved for Friedreich’s ataxia, improves mitochondrial bioenergetics and restores redox homeostasis. We investigated whether pharmacological activation of NRF2 (nuclear factor erythroid 2–related factor 2) by Omaveloxolone confers therapeutic benefit in pulmonary hypertension (PH). METHODS: The effects of Omaveloxolone were evaluated in chronic hypoxia-induced PH in mice, monocrotaline-induced PH in rats, and sugen/hypoxia-induced PH in rats, together with studies in human pulmonary artery endothelial and smooth muscle cells. RESULTS: NRF2 expression and nuclear localization were reduced in PH lungs and hypoxia-exposed cells, whereas Omaveloxolone restored NRF2 activity and increased downstream antioxidant enzymes. In endothelial cells, Omaveloxolone reduced oxidative stress, suppressed inflammatory signaling, and inhibited endothelial-to-mesenchymal transition. In smooth muscle cells, it attenuated oxidative stress and normalized abnormal proliferation, migration, and apoptosis. Omaveloxolone reduced HIF (hypoxia-inducible factor)-2α accumulation in endothelial cells and inhibited HIF-1α stabilization in smooth muscle cells. NRF2 knockdown attenuated these effects, supporting pathway dependency. Omaveloxolone attenuated PH, reduced right ventricular hypertrophy and vascular remodeling, and improved right ventricular function across hypoxia, monocrotaline, and sugen/hypoxia models under both preventive and therapeutic regimens. CONCLUSIONS: These findings demonstrate that Omaveloxolone exerts disease-modifying effects in PH by activating NRF2-dependent cytoprotective pathways, reducing oxidative stress, and suppressing inflammation, supporting its translational potential as a therapeutic strategy.
- Open Access
- 12 June 2026
- Published by Wiley in The Plant Journal
- Vol. 126 (5) , e70966
The fluorescence‐activating and absorption‐shifting tag ( FAST ), a versatile protein marker for live plant cell imaging
SUMMARY: The development of real‐time imaging has progressed spectacularly in recent years, largely due to the availability of multiple fluorophores with distinct spectral properties. This progress enables the simultaneous imaging of an increasing number of targets, providing access to complex biological processes occurring during development, signaling, and metabolism. In this study, we successfully tested the transfer of three different fluorescence‐activating and absorption‐shifting tags (FAST), originally developed in animal systems and yeast, to plants. These small (14 kDa) proteins associate non‐covalently and reversibly with specific chemicals known as fluorogens, generating bright fluorescence signals that can be reversibly eliminated by washing. This property offers versatile applications. Green‐ and Red‐FAST proteins were successfully used to label proteins targeted to several plant cellular compartments. In contrast, the latest generation of FAST proteins, identified in Rheinheimera sp. A13L ( RspA ), which accepts multiple fluorogens and offers broad versatility in excitation and emission spectra, was used with a split FAST version to demonstrate cytosolic protein–protein interactions.
- 12 June 2026
- Published by Wiley in The Plant Journal
- Vol. 126 (5) , e70966
Open AccessThe fluorescence‐activating and absorption‐shifting tag ( FAST ), a versatile protein marker for live plant cell imaging
SUMMARY: The development of real‐time imaging has progressed spectacularly in recent years, largely due to the availability of multiple fluorophores with distinct spectral properties. This progress enables the simultaneous imaging of an increasing number of targets, providing access to complex biological processes occurring during development, signaling, and metabolism. In this study, we successfully tested the transfer of three different fluorescence‐activating and absorption‐shifting tags (FAST), originally developed in animal systems and yeast, to plants. These small (14 kDa) proteins associate non‐covalently and reversibly with specific chemicals known as fluorogens, generating bright fluorescence signals that can be reversibly eliminated by washing. This property offers versatile applications. Green‐ and Red‐FAST proteins were successfully used to label proteins targeted to several plant cellular compartments. In contrast, the latest generation of FAST proteins, identified in Rheinheimera sp. A13L ( RspA ), which accepts multiple fluorogens and offers broad versatility in excitation and emission spectra, was used with a split FAST version to demonstrate cytosolic protein–protein interactions.
- Open Access
- 12 February 2026
- Published by MDPI AG in Preprints.org
Mitochondrial-Endoplasmic Reticulum Axis (MERA) in Pulmonary Hypertension: A Critical Inter-Organellar Crossroads for Pathogenesis and Therapeutic Targets
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized primarily by sustained pulmonary vasoconstriction, pulmonary vascular remodeling, and elevated pulmonary artery pressure. Recent emerging studies have indicated that mitochondria-endoplasmic reticulum (ER) membrane (MAM) is increasingly implicated in pathogenesis of pulmonary hypertension (PH). Dysfunction of mitochondria or ER can trigger a series of pathological processes, including disrupted intracellular Ca2+ homeostasis, oxidative stress, ER stress, and inflammation, which in turn drive dysfunction of pulmonary artery smooth muscle (PASMCs) and endothelial cells (PAECs). This review article aims to systematically evaluates the pathogenic mechanisms of the MAM in PH, covering the latest research advances in mitochondrial dynamic disorders, Ca2+ homeostasis, ER stress, oxidative stress, cellular metabolic reprogramming, and inflammatory responses. Special focus is placed on the structural and functional regulatory mechanisms of MAMs and their roles in pulmonary vascular functional and structural dysfunction. Furthermore, the current review also discusses the potential of new and efficacious therapeutic strategies targeting mitochondrial dysfunctions and ER stress for treatments of PH.
- 12 February 2026
- Published by MDPI AG in Preprints.org
Open AccessMitochondrial-Endoplasmic Reticulum Axis (MERA) in Pulmonary Hypertension: A Critical Inter-Organellar Crossroads for Pathogenesis and Therapeutic Targets
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized primarily by sustained pulmonary vasoconstriction, pulmonary vascular remodeling, and elevated pulmonary artery pressure. Recent emerging studies have indicated that mitochondria-endoplasmic reticulum (ER) membrane (MAM) is increasingly implicated in pathogenesis of pulmonary hypertension (PH). Dysfunction of mitochondria or ER can trigger a series of pathological processes, including disrupted intracellular Ca2+ homeostasis, oxidative stress, ER stress, and inflammation, which in turn drive dysfunction of pulmonary artery smooth muscle (PASMCs) and endothelial cells (PAECs). This review article aims to systematically evaluates the pathogenic mechanisms of the MAM in PH, covering the latest research advances in mitochondrial dynamic disorders, Ca2+ homeostasis, ER stress, oxidative stress, cellular metabolic reprogramming, and inflammatory responses. Special focus is placed on the structural and functional regulatory mechanisms of MAMs and their roles in pulmonary vascular functional and structural dysfunction. Furthermore, the current review also discusses the potential of new and efficacious therapeutic strategies targeting mitochondrial dysfunctions and ER stress for treatments of PH.